New Recruits
Welcoming new recruits
The UF Health Cancer Center is pleased to welcome 12 recruits who represent a wide range of research and clinical expertise.
Daohong Zhou, M.D.
College of Pharmacy, Department of Pharmacodynamics
Start Date: 3/1/18
Previous Institution: Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences
Research: Dr. Zhou’s research has been focused on investigation of the long-term effects of genotoxic stress/DNA damage induced by ionizing radiation (IR) and chemotherapy on hematopoietic stem cell (HSC) self-renewal and genomic stability; and the role of HSC injury in IR- and chemotherapy-induced long-term bone marrow suppression and leukemogenesis.
Guangrong Zheng, Ph.D.
College of Pharmacy, Department of Medicinal Chemistry
Start Date: 3/1/18
Previous Institution: University of Arkansas for Medical Sciences College of Pharmacy
Research: Dr. Zheng’s lab focuses on the design, synthesis and structure-activity relationship study of both synthetically derived and natural product-based compounds for potential therapeutic uses or as molecular probes for biochemical/pharmacological research.
Zhijian Qian, Ph.D.
College of Medicine, Division of Hematology & Oncology
Start Date: 3/9/18
Previous Institution: University of Illinois Cancer Center
Research: The long-term goal of Dr. Qian’s research is to understand the mechanisms that underlie the development of blood cancer with a focus on studying the genetic pathways that control the proliferation, survival and self-renewal of normal or leukemic hematopoietic stem cells.
Melike Caglayan, Ph.D.
College of Medicine, Department of Biochemistry and Molecular Biology
Start Date: 6/15/18
Previous Institution: National Institute of Environmental Health Sciences
Research: Dr. Caglayan’s work focuses on mechanisms of repair of cytotoxic and mutagenic DNA damage that can lead to genomic instability, a precursor to cancer.
Lina Cui, Ph.D.
College of Pharmacy, Department of Medicinal Chemistry
Start Date: 6/26/18
Previous Institution: University of New Mexico Comprehensive Cancer Center
Research: The Cui lab explores the biochemical activities of glycan processing enzymes and develops therapeutic and diagnostic molecules or tools for various types of cancer and age-related diseases.
Ji-Hyun Lee, DrPH
College of Medicine, College of Public Health and Health Professions, Department of Biostatistics
Start Date: 7/1/18
Previous Institution: University of New Mexico Comprehensive Cancer Center
Research: Dr. Lee’s research interests include clinical trial design, group randomized trials based on communities, methods for repeated measurements, Bayesian approach and best statistical practices.
Matthew Eddy, Ph.D.
College of Liberal Arts and Science, Department of Chemistry
Start Date: 8/16/18
Previous Institution: The Scripps Research Institute
Research: Dr. Eddy’s lab studies the structures and activities of human cell surface receptors in contexts that closely mimic the cellular environment and also directly in cells. The focus of the lab is to apply an integrative structural biology approach to unravel how the effects of the cellular environment and drugs can be rationally controlled to develop new therapies.
Ryan Kolb, Ph.D.
College of Medicine, Department of Pathology, Immunology and Laboratory Medicine
Start Date: 11/2/18
Previous Institution: University of Iowa
Research: Dr. Kolb’s primary research focus is on how changes in the tumor microenvironment, such as those caused by inflammation or obesity, effect the pathogenesis, tumor immunity and treatment of cancer.
Weizhou Zhang, Ph.D.
College of Medicine, Department of Pathology, Immunology and Laboratory Medicine
Start Date: 11/6/18
Previous Institution: University of Iowa
Research: Dr. Zhang’s primary research interest focuses on the pathogenesis and therapy of breast cancer. The Zhang Lab studies the dynamic interactions between cancer cells and various tumor microenvironment components especially immune cells during the pathogenesis of breast cancer.
Brian Ramnaraign, M.D.
College of Medicine, Division of Hematology & Oncology
Start Date: 7/1/19
Previous Institution: University of Pennsylvania
Research: Dr. Ramnaraign’s expertise and research interests are in the fields of genitourinary cancers and gastrointestinal cancers. He is interested in the role of targeted therapies and immunotherapies in providing personalized treatments to individuals with advanced cancers.
Jonathan Chatzkel, M.D.
College of Medicine, Division of Hematology & Oncology
Start Date: 7/22/19
Previous Institution: Moffitt Cancer Center
Research: Dr. Chatzel’s clinical and research interests include the care of patients with genitourinary cancers, including cancers of the kidney, bladder, prostate and testis. He believes strongly in delivering individualized care to each of his patients.
Ke Ning, M.D.
College of Medicine, Division of Hematology & Oncology
Start Date: 9/30/19
Previous Institution: Hendrick Cancer Center
Research: Dr. Ning is a board- certified medical oncologist with special interests in thoracic, head and neck, and cutaneous oncology. He brings compassion and individualized cancer care, with integration with the most up-to-date modalities of therapy to improve patient outcomes and quality of life.